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Background: The peripheral eosinophil count (PEC) tends to increase during the course of
acute eosinophilic pneumonia (AEP), and an initially elevated PEC is associated with milder dis-
ease. However, there is a lack of data regarding these phenomena and inflammatory process of
AEP.
Methods: We prospectively evaluated serial changes in serum interleukin (IL)-5 levels and the
correlation between the initial level of IL-5 and the PEC to investigate whether the initial PEC
indicates a resolving state of inflammation. We also evaluated serum tryptase levels to inves-
tigate the possibility of involvement of mast cell activity in AEP.
Results: Twenty-one AEP patients were included, and all patients improved within 10 days af-
ter corticosteroid treatment. The median initial serum IL-5 level among all patients was
561.0 pg/mL, which decreased to zero at 10 days of follow-up (nZ 15, P < 0.001). The median
initial serum tryptase level (detectable in 20 of 21 patients) was 3.7 ng/mL and decreased to a
median of 1.1 ng/mL at 10 days of follow-up (nZ 15, P < 0.001). The initial serum IL-5 and C-pneumonia; BAL, bronchoalveolar lavage; CRP, C-reactive protein; CT, computed tomography; FiO2,
oglobulin; IL, interleukin; IQR, interquartile range; LOD, limit of detection; PaO2, a partial pressure of
quantification; PEC, peripheral eosinophil count; ULOQ, upper limit of quantification; WBC, white
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1656 B.W. Jhun et al.reactive protein levels were positively correlated (PZ 0.009, rZ 0.556), and the initial serum
IL-5 level was inversely correlated with the initial PEC (P Z 0.004, r Z 0.603).
Conclusions: Our data suggest that IL-5 is an important cytokine involved in the recruitment of
eosinophils from peripheral blood into the lungs, that an initially elevated PEC is associated
with a resolving state of inflammation, and that mast cells are potentially involved in the in-
flammatory process of AEP.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Acute eosinophilic pneumonia (AEP), first described by
Allen et al. [1] in 1989 as a distinct disease entity, is an
uncommon inflammatory lung disease. AEP presents with
acute-onset respiratory symptoms, diffuse radiographic
infiltrates, and eosinophilic infiltration into the lung
without a known cause of pulmonary eosinophilia, such as
drugs, toxins, or parasite infestations [2,3]. The clinical
severity of respiratory distress associated with AEP varies
from mild [4] to severe [5]; however, most patients with
AEP exhibit uniquely rapid responses to systemic cortico-
steroid therapy without sequelae, even in fatal cases [5,6].
Studies on the pathophysiology of AEP have suggested
that unidentified inhaled antigens could be responsible for
the inflammatory process [7e9], and several recent studies
have revealed that specific inflammatory cytokines (inter-
leukin [IL]-5, IL-18, and IL-33) are associated with eosino-
phil recruitment into the lungs, degranulation, and
eosinophil survival [10e15]. However, there is a lack of
data regarding the details of the inflammatory process in
the active or resolving phase of the disease, largely because
of the rarity of AEP, which limits insight into its
pathophysiology.
Our institution is a military hospital with the highest
referral rate in the Republic of Korea. We encounter several
cases of AEP annually [4,6,16], and we have found recently
that an initially elevated PEC is associated with a milder
disease status upon admission compared with a normal PEC,
and that an initially elevated PEC is inversely correlated
with the levels of inflammatory markers such as C-reactive
protein (CRP) [6]. As described in previous studies, we
speculate that these phenomena may be explained by an
increase in the PEC as AEP resolves because of decreasing
chemotaxis of peripheral eosinophils to the lung, induced
by a decrease in stimulatory cytokines. This occurs in
combination with increased bone marrow eosinophil pro-
duction triggered earlier by stimulatory cytokines such as
IL-5. As a result, PEC may rise temporarily and normalize
later.
However, these phenomena cannot be explained fully by
the results of previous studies. Therefore, in the present
study, we prospectively evaluated serial changes in serum
levels of IL-5 that play important roles in eosinophil acti-
vation during the course of treatment and the correlation
between the initial levels of IL-5 and PEC. Our goal was to
investigate whether initial peripheral eosinophilia repre-
sents a resolving state of the inflammatory process. We also
aimed to identify the serum level of tryptase that reflectsmast cell activation to investigate inflammatory cells other
than eosinophils that may be involved in the inflammatory
process of AEP.
Methods
Study subjects
Patients diagnosed with AEP were recruited prospectively
from 1 May 2013 and 1 January 2014 at the Armed Forces
Capital Hospital (874-bed military referral hospital) in
Gyeonggi Province, Republic of Korea.
A definite diagnosis of AEP was based on a modification
of the criteria proposed by Philit et al. [3] as reported
previously at our institution [4]: 1) acute onset of febrile
respiratory manifestations < 1 month in duration, regard-
less of hypoxemia; 2) bilateral diffuse infiltrates on chest
radiographs; 3) >25% eosinophils on bronchoalveolar lavage
(BAL) analysis or eosinophilic pneumonia on lung biopsy;
and 4) the absence of known causes of pulmonary eosino-
philia, such as drugs, toxins, and infections.
Diagnostic procedures including flexible bronchoscopy
using BAL and sampling for inflammatory cytokines were
performed after obtaining informed consent from the study
patients. The present study was approved by the Armed
Forces Capital Hospital Institutional Review Board, which
permitted review and publication of patient records (AFMC-
13-IRB-043).
Patient management and data collection
Patients who were initially suspected to have AEP at
admission underwent a diagnostic workup involving labo-
ratory examinations, chest radiography, computed tomog-
raphy (CT), and flexible bronchoscopy using BAL. Infectious
etiologies were investigated thoroughly in peripheral blood,
sputum, and BAL fluid using the following techniques:
staining and microbiological culture for bacteria and
Mycobacterium tuberculosis, multiplex polymerase chain
reaction for respiratory viruses including influenza virus,
para-influenza virus, adenovirus, and respiratory syncytial
virus, and serological testing for atypical pathogens
including Mycoplasma pneumoniae, Chlamydia pneumo-
niae, and parasites.
All patients diagnosed with AEP were treated using a
protocol described previously [4] according to the presence
of respiratory failure, defined as a partial pressure of
arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2)
Eosinophil and mediators in AEP 1657ratio  300 and/or tachypnea (respiration rate > 30
breaths/min). When the patient had respiratory failure,
60 mg methylprednisolone was administered intravenously
every 6 h for 3 days and then changed to 30 mg oral pred-
nisolone twice per day. When the patient had no respiratory
failure, 30 mg oral prednisolone was administered twice per
day. The duration of corticosteroid tapering was 2 weeks.
When the oxygenation situation was not severe (PaO2/FiO2
ratio > 350) and symptoms were mild, the patient received
conservative treatment without corticosteroids.
The patients’ baseline characteristics and clinico-
radiologic findings were recorded, and serum levels of IL-
5, tryptase, and inflammatory markers, including white
blood cell (WBC) count with CRP level, were obtained at
the time of the diagnosis of AEP before starting cortico-
steroid treatment. All data were followed up on the 10th
hospital day. The CD4/CD8 ratio and WBC count with dif-
ferential using BAL fluid at diagnosis were also obtained.
Serum immunoglobulin (Ig) E levels were also obtained at
diagnosis and at follow-up.
Measurement of serum IL-5 and tryptase
Serum IL-5 levels were measured using a human IL-5
enzyme-linked immunosorbent assay (ELISA) kit (Quanti-
kine Human Immunoassay; R&D Systems, Minneapolis, MN,
USA). Serum total tryptase was assayed using the Immu-
noCAP Tryptase kit (Phadia AB, Uppsala, Sweden), which
measures both immature and mature a/b-tryptase, with
the ImmunoCap 1000 fluorescence enzyme immunoassay
analyzer (Phadia AB).
The limit of detection (LOD), lower limit of quantifica-
tion (LLOQ), and upper limit of quantification (ULOQ) for
each cytokine/chemokine according to the manufacturer
were as follows: IL-5 (1.08 pg/mL, 3.9e250 pg/mL) and
tryptase (0.1 ng/mL, 1e200 ng/mL). LOD was determined
by taking the mean optical density plus two standard de-
viations from 20 replicates of the zero calibrator. This value
was converted into an analyte concentration from the
standard curve. LLOQ and ULOQ were verified using the
following trueness and precision criteria: both relative
error and coefficient of variation <30%. Thus, serum IL-5
and tryptase concentrations below the LLOQ were deemed
to be zero in our analyses.
Bronchoscopy using BAL
After obtaining written informed consent from the study
patients, bronchoscopy using BAL was performed at the
time of presentation using a flexible fiberoptic broncho-
scope under local anesthesia with 2% lidocaine. BAL was
performed using a standard technique described previously
[17]. Once wedged, normal saline at room temperature
(30 mL) was instilled through the bronchoscope and then
retrieved using negative suction pressure adjusted to avoid
visible airway collapse (<100 mmHg). The procedure was
then repeated until a total of at least 120 mL had been
instilled. We attempted to obtain adequate BAL fluid of at
least 20e30 mL and when the volume of fluid recovered was
insufficient, an additional 20e30-mL saline were injected
and suctioned. The percentages of eosinophils in the BALfluid were determined on cytocentrifuged slides using
standard criteria.Statistical analyses
Data are presented as medians and interquartile ranges
(IQR) for continuous variables and as numbers and per-
centages for categorical variables. Wilcoxon’s signed-rank
test was performed to evaluate changes in the levels of
inflammatory mediators during the course of treatment.
Spearman’s correlation coefficient analysis was performed
to evaluate correlations among inflammatory mediators
and markers. All statistical analyses were performed using
the PASW software (ver. 18.0; SPSS Inc., Chicago, IL, USA)
and a two-sided P-value < 0.05 was considered to indicate
statistical significance.Results
Characteristics of the study patients
In total, 21 consecutive patients with AEP were included.
Characteristics of the patients are shown in Table 1. All
patients were male with a median age of 20 (IQR, 19e21)
years. All were current smokers, and none had a history of
allergic disease. All patients presented with respiratory
symptoms, such as cough, sputum, and dyspnea, and had
abnormal radiologic findings including diffuse ground glass
opacities (Fig. 1AeC).
On BAL fluid analysis, the median WBC count was 600
(IQR, 455e1150)/mL, with a median eosinophil percentage
of 51 (IQR, 36e66) %, and the median CD4/CD8 ratio was 1.5
(IQR, 1.1e1.7). On laboratory tests in peripheral blood,
WBC counts were elevated (>10,000/mL) in 14 (67%) pa-
tients, with a median of 12,780 (IQR, 8940e17,030)/mL and
CRP was elevated in all patients, with a median of 7.29
(IQR, 3.62e15.44) mg/dL.
Most patients (nZ 20, 95%) were treated with a 2-week
corticosteroid course, and one (5%) patient underwent
conservative treatment. All patients showed subsequent
clinico-radiological recovery during hospitalization. The
median total hospital stay was 10 (IQR, 9e12) days.Serial changes in serum IL-5 and tryptase levels
along with treatment responses
As shown in Table 2, all respiratory symptoms and abnormal
radiological findings resolved completely within 10 hospital
days in all 21 patients (Fig. 1C and D), and follow-up data
for serum IL-5, tryptase, and IgE levels on day 10 were
available for 15 of the 21 patients.
Serum IL-5 was detected in all 21 patients with a median
level of 561.0 (IQR, 265.5e794.0; range, 10.0e2448.0) pg/
mL on day 1. It decreased subsequently to zero on day 10 in
all patients followed, and the difference was statistically
significant (P < 0.001) (Fig. 2A). Serum tryptase on day 1
was detectable in 20 of 21 patients and zero in one patient,
with a median of 3.7 (IQR, 1.8e4.4; range, 0.0e6.0) ng/mL.
On day 10, serum tryptase decreased to a median of 1.1
Table 1 Baseline characteristics of study patients.
Characteristic Value
Patient 21 (100)
Age (years) 20 (19e21)
Sex (male) 21 (100)
Current smoker 21 (100)
Recently started smoking 15/21 (71)
Resumed smoking 5/21 (24)
Increased the number of
cigarettes
1/21 (5)
Respiratory symptoms 21 (100)
Abnormal radiologic findings
Ground glass opacity 21 (100)
Interlobular septal thickening 17 (81)
Pleural effusion 11 (52)
BAL fluid analysis
White blood cell count (/mL) 600 (455e1150)
Neutrophil (%) 2 (0e6)
Lymphocyte (%) 22 (15e40)
Eosinophil (%) 51 (36e66)
CD4/CD8 ratio 1.5 (1.1e1.7)
Laboratory tests in peripheral
blood
White blood cell count (/mL) 12,780 (8940e17,030)
Neutrophil (%) 78 (71e87)
Eosinophil (%) 1.8 (1.5e5.8)
Peripheral eosinophil count (/mL) 290 (185e574)
C-reactive protein (mg/dL) 7.29 (3.62e15.44)
Need for mechanical ventilation 0 (0)
Treatment 21 (100)
2-week corticosteroid treatment 20 (95)
Conservative treatment 1 (5)
Total hospital stay (days) 10 (9e12)
Survival 21 (100)
Data are shown as medians (interquartile range) or no. (%). BAL,
bronchoalveolar lavage; CD4/CD8 ratio data are missing in two
cases.
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statistically significant (P < 0.001) (Fig. 2B).
During the course of treatment, CRP levels decreased
significantly (P < 0.001). However, changes in WBC count
(P Z 0.140) with differential (P Z 0.053 for neutrophil
percentage, P Z 0.460 for eosinophil percentage) and PEC
(P Z 0.776) were not statistically significant. Ten patients
had a serum IgE >100 kU/L on day 1, and serum IgE levels
tended to decrease during treatment; however, the dif-
ference was not statistically significant (P Z 0.091).
Correlations among serum IL-5, tryptase, and
inflammatory markers
We also evaluated correlation coefficients among initial
serum IL-5, tryptase, and inflammatory markers upon
admission. As shown in Fig. 3, there was a significant pos-
itive correlation between the initial levels of serum IL-5 and
CRP (PZ 0.009, rZ 0.556) (Fig. 3A), and the initial serum
IL-5 was correlated inversely and significantly with the
initial PEC (PZ 0.004, rZ e 0.603) (Fig. 3B) and the initialperipheral eosinophil percentage (P Z 0.002, r Z 0.638)
(not shown in Fig. 3). However, there was no significant
correlation between the initial levels of serum tryptase and
CRP (P Z 0.347, r Z 0.216) (Fig. 4A) or between the
initial levels of serum tryptase and the initial PEC
(P Z 0.376, r Z 0.204) (Fig. 4B).
There was a significant positive correlation between the
initial CD4/CD8 ratio and serum IgE level (P Z 0.037,
r Z 0.510). However, there was no significant correlation
between the serum IL-5 and tryptase levels (P Z 0.471,
r Z 0.167), serum IL-5 and IgE levels (P Z 0.538,
r Z 0.151), or tryptase and serum IgE levels (P Z 0.963,
r Z 0.011).Discussion
In the present study, we investigated serial changes in
serum IL-5 and tryptase levels during the course of treat-
ment and evaluated correlations among serum IL-5, tryp-
tase, and inflammatory markers. The most important
findings in our study were the significant inverse correlation
between the initial IL-5 level and PEC (P Z 0.004,
r Z 0.603) and the dramatic decrease in the serum IL-5
level with clinical improvement. Regarding the PEC in pa-
tients with AEP, a few previous studies have indicated that
the PEC tends to increase temporarily during the course of
treatment [3,4,8,9,18,19]. We recently investigated the
clinical implications of initial peripheral eosinophilia in 85
patients with AEP [6], in that study, we found that the PEC
tended to increase along with clinical improvement and
that an initially elevated PEC was associated clearly with a
clinically milder disease status on admission than was a
normal PEC. With respect to this phenomenon, eosinophils
differentiate from hematopoietic stem cells in the bone
marrow and migrate into the blood where they circulate,
with a half-life of approximately 18 h, before entering the
tissue; thus, we cautiously speculate that the correlation
between the initial PEC and a milder disease status might
have been caused by decreased chemotaxis of peripheral
eosinophils into the lungs. This is because the levels of
stimulatory mediators, such as IL-5, decreased and over-
lapped with an earlier increase in bone marrow eosinophil
production in patients who exhibited disease resolution
upon admission. In this context, our data on the inverse
correlation between the initial IL-5 level and PEC may
support this speculation and suggest that IL-5 is an impor-
tant inflammatory cytokine involved in the recruitment of
eosinophils from peripheral blood into the lung. An initially
elevated PEC may imply a resolving disease state, helping
to stratify the disease severity in patients with AEP.
In the present study, the serum IL-5 level dramatically
decreased with clinical improvement and showed a signifi-
cant positive correlation with the CRP level. The serum IL-5
level decreased to zero after 10 days of treatment, even in
one patient whose level was as high as 2448.0 pg/mL upon
initial presentation. IL-5 is a specific cytokine that plays
important roles in the recruitment, degranulation, and
survival of eosinophils, and previous studies have demon-
strated elevated IL-5 levels in both the serum and BAL fluid
of patients with active AEP [13,15]. However, previous
studies did not show serial changes with clinical
Figure 1 Radiologic examination findings in a 20-year-old male patient with acute eosinophilic pneumonia. Chest CT on
admission shows (A) diffuse ground-glass opacity and interlobular septal thickening in both lungs and (B) right pleural effusion.
Chest radiography obtained after 10 days of corticosteroid treatment shows (D) complete resolution of the (C) previously abnormal
radiographic findings.
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important inflammatory mediator involved in maintaining
active inflammatory processes. However, to date, data that
fully explain the inflammatory process of AEP are limited;
further studies on the pathophysiology of AEP are needed.
Although the initial serum tryptase level among our pa-
tients was not sufficiently elevated to diagnose mastocy-
tosis or anaphylaxis (>11.4 ng/mL) [20], most patients
(95%, n Z 20) upon admission had detectable levels of
serum tryptase, which decreased significantly during
follow-up in those patients who exhibited clinicalTable 2 Serial changes in clinical, radiological, and laboratory
Characteristics Day 1
Respiratory symptoms 21 (100
Abnormal radiologic findings 21 (100
Laboratory findings in peripheral blood
White blood cell count (/mL) 12,780
Neutrophil (%) 78 (71e
Eosinophil (%) 1.8 (1.5
Peripheral eosinophil count (/mL) 290 (18
C-reactive protein (mg/dL) 7.29 (3
Serum IL-5 (pg/mL) 561.0 (
Serum tryptase (ng/mL) 3.7 (1.8
Serum IgE (kU/L) 154.0 (
Data are shown as medians (interquartile range) or no. (%). IL, interleu
and IgE at day 10 were missing in 6 cases.improvement. To our knowledge, no previous reports have
addressed the changes in serum tryptase levels, which may
reflect mast cell activation in patients with AEP. To date,
only one reported study has assessed tryptase levels in BAL
fluid from patients with chronic eosinophilic pneumonia. In
that study, the tryptase level in BAL fluid was higher in
patients with chronic eosinophilic pneumonia than in
healthy controls [21]. One previous study indirectly sug-
gested the possibility that additional inflammatory media-
tors play a role in the inflammatory process of AEP.
Watanabe et al. [8] reported a case of AEP followingfindings during the course of treatment.
Day 10
) Complete resolution
) Complete resolution
(8940e17,030) 12,890 (11,580e16,850)
87) 70 (55e80)
e5.8) 1.4 (0.3e5.6)
5e574) 200 (53e1052)
.62e15.44) 0.04 (0.012e0.076)
265.5e794.0) 0 (0)
e4.4) 1.1 (0.0e1.8)
59.4e312.0) 99.3 (43.2e385.0)
kin; Ig, immunoglobulin. Follow-up data for serum IL-5, tryptase,
Figure 3 (A) Correlations between the initial levels of serum IL-5 and CRP and (B) between levels of serum IL-5 and the initial
PEC.
Figure 4 (A) Correlations between the initial levels of serum tryptase and CRP and (B) between initial levels of serum tryptase
and the initial PEC.
Figure 2 Serial changes in serum levels of (A) IL-5 and (B) tryptase on hospital days 1 and 10.
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the patient showed no symptoms, normal chest CT findings,
and no increase in the CD4/CD8 ratio compared with at the
time of AEP onset, despite the fact that the eosinophil
percentage in BAL fluid increased to 65%. These data sug-
gest that in addition to eosinophils, other inflammatory
cells could be involved in triggering or maintaining inflam-
matory processes. In this context, our data suggest the
possible involvement of mast cell activity in the patho-
physiology of AEP. However, only limited data exist so far,
and further well-designed studies on the possible role of
mast cells are needed.
Interestingly, 10 patients in our study had elevated
serum IgE levels (>100 kU/L) upon admission, which tended
to decrease over the course of treatment, although not
significantly (PZ 0.091). Additionally, the initial serum IgE
level was correlated significantly and positively with the
CD4/CD8 ratio (PZ 0.037, r Z 0.510). Imokawa et al. [22]
reported elevated serum IgE levels in three patients with
AEP [22]. Hayakawa et al. [23] also compared the clinical
characteristics of 13 patients with AEP with those of 14
patients with chronic eosinophilic pneumonia and found
that the serum IgE level tended to be higher in the patients
with AEP, although not significantly. These findings may
suggest the possibility of that AEP is associated with IgE-
mediated inflammation. However, no accurate data are
available on the role of IgE in AEP. Previous studies are
subject to various limitations that affect the interpretation
of the elevated serum IgE in patients with AEP because the
reported serum IgE levels vary considerably, and none of
the studies included a sufficient number of patients or
performed long-term follow-up of serum IgE levels. Thus,
further investigations of the role of serum IgE in AEP
pathophysiology are needed.
In the present study, changes in the PEC were not sig-
nificant after 10 days of corticosteroid treatment, despite
a significant decrease in CRP levels. This phenomenon
could be explained by the fact that the PEC tended to
increase temporarily and later normalized with clinico-
radiological improvement, as described previously
[6,18,19]. In our study, 16 (76%) patients had an initially
normal PEC and 5 (24%) patients had an initially elevated
PEC (>500/mL), and after corticosteroid treatment, PEC
increased in 7 of the former 16 patients and decreased in
all of the latter 5 patients, which could explain the lack of
statistically significant changes in PEC between day 1 and
day 10.
The current study has several limitations. First, mea-
surement of inflammatory cytokines in BAL fluid was not
performed. This might have provided greater insight into
the inflammatory process of AEP, given that the initial
insult in AEP occurs primarily in the lungs. Second, follow-
up laboratory data regarding serum IL-5 and tryptase levels
were missing in some patients, and long-term follow-up to
assess inflammatory mediators such as IgE during the
course of treatment was not performed. Finally, our pop-
ulation was not representative for age or sex because our
study was performed at a military hospital, all patients
were previously healthy males with a median age of 20
years, and this is not representative of the general popu-
lation. Thus, further well-designed prospective studies are
needed.Conclusions
Our data suggest that IL-5 is an important cytokine involved
in the recruitment of eosinophils from peripheral blood into
the lung, that an initially elevated PEC is associated with a
resolving state of inflammation, and that mast cell activity
is potentially involved in AEP.
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